MBP metabolic pharmaceuticals limited

In an earlier post on the Investor Update, I went through my...

  1. 5,318 Posts.
    lightbulb Created with Sketch. 253
    In an earlier post on the Investor Update, I went through my reasons why the company might choose to send the data to multiple "independent experts".

    Briefly, I believe that the blind has not been lifted as yet, but because of the peculiar nature of the crossover study, the results can be seen through the blind.

    The analysis of the data will take some time, and if the entirety of the results are given to one organization to analyze, the researchers and analysts will quickly see through the data and confidentiality will be breached.

    One way to avoid this is to parcel out the analysis to several independent experts none of who see the entire sample. I believe that this is precisely the situation that the company succinctly described in the update.

    Of course, it would take a bit of time to identify and enlist the appropriate "independent experts", and I think that could be the cause of the delay so far. I have no doubt that if the analysis of the data had been done straightaway by one organization, we'd already have the results.

    Once the independent experts have completed their work and reported back, the blind can be lifted, the final consolidation of the data and reporting can be done over the four days or so that a normal Thursday-Friday trading halt would provide.

    I don't think that the present process is being driven by any kind of ambiguity in the data.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.